Azeliragon ameliorates Alzheimer's disease via the Janus tyrosine kinase and signal transducer and activator of transcription signaling pathway.

Abstract

OBJECTIVES:

TTP488, an antagonist of the receptor for advanced glycation end-products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD). However, the mechanism underlying the protective action of TTP488 against AD has not yet been fully explored.

METHODS:

Healthy male rats were exposed to aberrant amyloid β (Aβ) 1-42. Lipopolysaccharide (LPS) and the NOD-like receptor family pyrin domain containing 1 (NLRP1) overexpression lentivirus were injected to activate the NLRP1 inflammasome and exacerbate AD. TTP488 was administered to reverse AD injury. Finally, tofacitinib and fludarabine were used to inhibit the activity of Janus tyrosine kinase (JAK) and signal transducer and activator of transcription (STAT) to prove the relationship between the JAK/STAT signaling pathway and TTP488.

RESULTS:

LPS and NLRP1 overexpression significantly increased the NLRP1 levels, reduced neurological function, and aggravated neuronal damage, as demonstrated by the impact latency time of, time spent by, and length of the platform covered by, the mice in the Morris water maze assay, Nissl staining, and immunofluorescence staining in rats with AD.

CONCLUSIONS:

TTP488 administration successfully reduced AD injury and reversed the aforementioned processes. Additionally, tofacitinib and fludarabine administration could further reverse AD injury after the TTP488 intervention. These results suggest a new potential mechanism underlying the TTP488-mediated alleviation of AD injury.

• Authors: Lijuan Yang, Yepei Liu, Yuanyuan Wang, Junsheng Li, Na Liu
• Journal: Clinics (Sao Paulo, Brazil) (Clinics (Sao Paulo)) Vol. 76 Pg. e2348 ( 2021) ISSN: 1980-5322 [Electronic] United States
• PMID: 33681944 (Publication Type: Journal Article)

Chemical References

• Amyloid beta-Peptides
• Imidazoles
• Receptor for Advanced Glycation End Products
• STAT Transcription Factors
• Tyrosine
• Janus Kinase 2
• Janus Kinases
• azeliragon

Topics

• Alzheimer Disease (drug therapy)
• Amyloid beta-Peptides
• Animals
• Imidazoles (pharmacology)
• Janus Kinase 2
• Janus Kinases (metabolism)
• Male
• Mice
• Rats
• Receptor for Advanced Glycation End Products
• STAT Transcription Factors (metabolism)
• Signal Transduction
• Tyrosine